Enhanced AE2 promotes ovarian cancer progression by activating mTOR signaling [17]; whereas, reduction of AE2 enhances cellular migration via the activation of MMP pathways in the esophageal squamous cell carcinoma [31]. This evidence concerns the gene MTOR and ovarian carcinoma.